Surgery Partners Q4 revenue +4% to $735.4M; FY Adjusted EBITDA $438.1M; guides 2024 revenue >$3B

Surgery Partners, Inc.

2023-FY EPS reported -$0.09 revenue$2,743,300,000

Q4 revenue $735.4M (+4.0% YoY); full-year revenue $2.74B (+8.0% YoY).
Q4 Adjusted EBITDA $142.3M (+17.8% YoY); FY Adjusted EBITDA $438.1M (+15.2% YoY).
Days adjusted same-facility revenue +8.1% Q4, +11.3% full year vs 2022.
Net loss attributable to common: $1.0M Q4, $11.9M full year 2023.
2024 guidance: revenue >$3.0B, Adjusted EBITDA >$495M; liquidity ~$900M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Surgery Partners, Inc. updated its fourth quarter and full year ended December 31, 2023 guidance (reaffirmed).

Period: fourth quarter and full year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 26, 2024, Surgery Partners, Inc. issued a press release announcing results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Surgery Partners, Inc. filing history →

Source: SEC EDGAR

accession 0001638833-24-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.